Cargando…

Successful treatment of metastatic urothelial carcinoma arising in a transplanted renal allograft with paclitaxel, cisplatin, and gemcitabine combination therapy: a case report

BACKGROUND: For locally advanced or metastatic urothelial carcinoma, cisplatin-based chemotherapy is the standard regimen. Nevertheless, almost all responding patients experience recurrence within the first year. When patients who have received prior cisplatin-based therapy become resistant, combina...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kojima, Yasuyuki, Takahi, Yuko, Ichimaru, Naotsugu, Okumi, Masayoshi, Takahara, Shiro, Nonomura, Norio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4323029/ https://www.ncbi.nlm.nih.gov/pubmed/25648269 http://dx.doi.org/10.1186/s13104-015-0982-6

Ejemplares similares

Early diagnosis and treatment of breast cancer in Japanese kidney transplant recipients: a single center experience
por: Kato, Taigo, et al.
Publicado: (2015)

The benefits of cancer screening in kidney transplant recipients: a single‐center experience
por: Kato, Taigo, et al.
Publicado: (2015)

Non-Invasive Magnetic Resonance Imaging in Rats for Prediction of the Fate of Grafted Kidneys from Cardiac Death Donors
por: Kaimori, Jun-Ya, et al.
Publicado: (2013)

Safety and efficacy of combination therapy with low-dose gemcitabine, paclitaxel, and sorafenib in patients with cisplatin-resistant urothelial cancer
por: Miyata, Yasuyoshi, et al.
Publicado: (2015)

Comparison of full-dose gemcitabine/cisplatin, dose-reduced gemcitabine/cisplatin, and gemcitabine/carboplatin in real-world patients with advanced urothelial carcinoma
por: Sugimoto, Kazuma, et al.
Publicado: (2022)

A pilot study of gemcitabine and paclitaxel as third-line chemotherapy in metastatic urothelial carcinoma
por: Naiki, Taku, et al.
Publicado: (2017)

Impact of relative dose intensity in gemcitabine–cisplatin chemotherapy for metastatic urothelial carcinoma
por: Kohei, Naoki, et al.
Publicado: (2018)

iPSC-Derived Regulatory Dendritic Cells Inhibit Allograft Rejection by Generating Alloantigen-Specific Regulatory T Cells
por: Cai, Songjie, et al.
Publicado: (2017)

Monotherapy With Anti-CD70 Antibody Causes Long-Term Mouse Cardiac Allograft Acceptance With Induction of Tolerogenic Dendritic Cells
por: Zhao, Jing, et al.
Publicado: (2021)

Use of low-dose combined therapy with gemcitabine and paclitaxel for advanced urothelial cancer patients with resistance to cisplatin-containing therapy: a retrospective analysis
por: Miyata, Yasuyoshi, et al.
Publicado: (2012)

Compensatory combination of romidepsin with gemcitabine and cisplatin to effectively and safely control urothelial carcinoma
por: Pattarawat, Pawat, et al.
Publicado: (2020)

Gemcitabine–Paclitaxel Chemotherapy for Patients with Advanced Urothelial Cancer Refractory to Cisplatin-Based Chemotherapy: Predictive Role of PGK1 for Treatment Response to Cytotoxic Chemotherapy
por: Koguchi, Dai, et al.
Publicado: (2022)

Protective effects of hydrogen gas inhalation on radiation-induced bone marrow damage in cancer patients: a retrospective observational study
por: Hirano, Shin-ichi, et al.
Publicado: (2021)

Sequential Therapy with Gemcitabine and Carboplatin Followed by Paclitaxel as First Line Treatment for Advanced Urothelial Cancer
por: Kattan, Joseph G, et al.
Publicado: (2012)

An Unusual Presentation of Metastatic BK Virus-Associated Urothelial Carcinoma Arising in the Allograft, Persisting After Transplant Nephrectomy
por: Jones, Heather, et al.
Publicado: (2023)

Neoadjuvant Nivolumab Plus Gemcitabine/Cisplatin Chemotherapy in Muscle-Invasive Urothelial Carcinoma of the Bladder
por: Kim, Hongsik, et al.
Publicado: (2023)

Gemcitabine–cisplatin versus MVAC chemotherapy for urothelial carcinoma: a nationwide cohort study
por: Lee, Yong Seong, et al.
Publicado: (2023)

Molecular hydrogen protects against ischemia-reperfusion injury in a mouse fatty liver model via regulating HO-1 and Sirt1 expression
por: Li, Shaowei, et al.
Publicado: (2018)

Phase I Study of Everolimus in Combination with Gemcitabine and Split-Dose Cisplatin in Advanced Urothelial Carcinoma
por: Abida, Wassim, et al.
Publicado: (2016)

Durable response for ampullary and duodenal adenocarcinoma with a nab‐paclitaxel plus gemcitabine ± cisplatin combination
por: Cen, Putao, et al.
Publicado: (2019)

Modified MVAC as a Second-Line Treatment for Patients with Metastatic Urothelial Carcinoma after Failure of Gemcitabine and Cisplatin Treatment
por: Lee, Jung Hyun, et al.
Publicado: (2014)

Cisplatin shows greater efficacy than gemcitabine when combined with nab-paclitaxel in metastatic triple-negative breast cancer
por: Li, Yi, et al.
Publicado: (2019)

Serum phosphate levels modify the impact of parathyroid hormone levels on renal outcomes in kidney transplant recipients
por: Doi, Yohei, et al.
Publicado: (2020)

Probiotics enhances anti‐tumor immune response induced by gemcitabine plus cisplatin chemotherapy for urothelial cancer
por: Miyake, Makito, et al.
Publicado: (2022)

Pre-treatment metastatic growth rate is associated with clinical outcome in patients with metastatic renal cell carcinoma treated with nivolumab
por: Matsumura, Soichi, et al.
Publicado: (2023)

Pathologic Response Rates of Gemcitabine/Cisplatin versus Methotrexate/Vinblastine/Adriamycin/Cisplatin Neoadjuvant Chemotherapy for Muscle Invasive Urothelial Bladder Cancer
por: Lee, Franklin C., et al.
Publicado: (2013)

Tumor Volume Reduction After Gemcitabine Plus Cisplatin Induction Chemotherapy in Locally Advanced Nasopharyngeal Cancer: Comparison with Paclitaxel and Cisplatin Regimens
por: Zheng, Li, et al.
Publicado: (2018)

Urothelial Carcinoma in an Allograft kidney
por: Hejlesen, Maria Baand, et al.
Publicado: (2022)

Successful recovery from coronavirus disease 2019 in a living kidney transplant recipient using low‐dose methylprednisolone
por: Tanaka, Ryo, et al.
Publicado: (2020)

Multimodality Imaging Diagnosis of Multiple Ventricular Thrombosis and Massive Stroke after Gemcitabine and Cisplatin Chemotherapy for Urothelial Cancer
por: Bassareo, Pier Paolo, et al.
Publicado: (2019)

Timing of changing therapy from gemcitabine and cisplatin chemotherapy based on real-world data of advanced urothelial carcinoma
por: Furubayashi, Nobuki, et al.
Publicado: (2020)

Neoadjuvant chemotherapy with gemcitabine and cisplatin followed by selective bladder preservation chemoradiotherapy in muscle-invasive urothelial carcinoma of bladder
por: Sung, Hyun Hwan, et al.
Publicado: (2022)

Impact of Immunoglobulin M-Type Donor-Specific Human Leukocyte Antigen–Antibody Levels in Supernatants from Cultured Peripheral Blood Mononuclear Cells as Predictors of Antibody-Mediated Rejection
por: Imamura, Ryoichi, et al.
Publicado: (2020)

Treatment impact of newly approved therapeutic agents for metastatic urothelial carcinoma in Japan: a single-center retrospective study
por: Inoue, Yuta, et al.
Publicado: (2023)

Clinical Application of TERT Promoter Mutations in Urothelial Carcinoma
por: Hayashi, Yujiro, et al.
Publicado: (2021)

Efficacy of methotrexate/vinblastine/doxorubicin cisplatin combination in gemcitabine-pretreated patients with advanced urothelial cancer: a retrospective analysis
por: Karadimou, Alexandra, et al.
Publicado: (2010)

Bladder preservation in complicated invasive urothelial carcinoma following treatment with cisplatin/gemcitabine plus tislelizumab: A case report
por: Yang, Rui, et al.
Publicado: (2023)

Gemcitabine/paclitaxel: Interstitial pneumonia: case report
Publicado: (2021)

Comparison of gemcitabine plus nab-paclitaxel and FOLFIRINOX in metastatic pancreatic cancer
por: Han, Sung Yong, et al.
Publicado: (2020)

Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer
por: Chiorean, E Gabriela, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_b9sk44dk46d15vjofvikqm9j9b